HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
IBRX
ImmunityBio Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $7.93B
Market Cap
$7.93B
Enterprise Val
$8.80B
P/E Ratio
-7.99
P/B Ratio
-7.58
Trailing PEG (1Y)
-0.07
As Of
Aug 13, 2026

Overview & Key Metrics

Reporting period: Jun 30, 2026 · Q2 2026
Book Value-$1.05B
Gross Margin99.42%
Profit Margin99.42%
Return on Equity134.95%
Return on Assets-172.88%
Current Ratio5.72
Debt/Equity-1.17
LT Debt/Equity-1.17
Revenue Per Share0.05

Income Statement

Jun 30, 2026
Revenue$51.2M
Cost of Revenue$298.0K
Gross Profit$50.9M
R&D$60.8M
SG&A$51.8M
Operating Expenses$112.6M
Operating Income-$61.7M
Interest Expense$31.2M
Tax Expense$0.00
Net Income-$230.4M
EPS (Basic)$-0.22
EPS (Diluted)$-0.22
EBIT-$199.1M
EBITDA-$193.0M
Consolidated Income-$230.4M
Non-Controlling Interests-$12.0K

Balance Sheet

Jun 30, 2026
Cash & Equivalents$75.7M
Accounts Receivable$53.5M
Inventory$18.4M
Current Assets$439.0M
LT Investments$0.00
Property, Plant & Equipment$145.5M
Intangibles$11.8M
Non-Current Assets$189.5M
Total Assets$628.5M
Accounts Payable$13.5M
Current Debt$7.5M
Current Liabilities$76.7M
LT Debt$1.22B
Non-Current Liabilities$1.60B
Total Liabilities$1.67B
Total Debt$1.23B
Retained Earnings-$4.59B
Shareholder Equity-$1.05B
Shares Outstanding1,047,353,977

Cash Flow Statement

Jun 30, 2026
Operating Cash Flow-$66.5M
Investing Cash Flow-$107.5M
Financing Cash Flow$44.4M
CapEx-$3.5M
Free Cash Flow-$70.0M
Depreciation & Amort.$6.2M
Stock-Based Comp$8.5M
Acquisitions / Disposals$0.00
Investment Activity-$103.9M
Debt Issued/Repaid-$898.0K
Equity Issued/Repaid$45.4M
Dividends Paid$0.00
Net Change in Cash-$129.5M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h